Related Experiment Video
Updated: Apr 18, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Progress in new diagnosis and therapeutic strategy for gastrointestinal malignancy: focus on new molecular-targeted
1Department of Gastroenterology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Abstract:
The core symposiums of the Japanese Gastroenterological Association (JGA) annual scientific meetings focus on similar topics from year to year. The main topics of these symposiums for the last 3 years were centered on progress in new diagnostics and therapeutic strategies for gastrointestinal malignancy, with a special focus on new molecular-targeted treatments for gastrointestinal stromal tumors (GIST), neuroendocrine tumors (NET) and other gastrointestinal (GI) cancers, including malignant lymphoma, for which new molecular-targeted treatments are now being commonly used. The 8th annual meeting of the JGA was held in 2012 and 8 excellent papers were presented on progress in new diagnostics and therapy for GIST. The 9th annual meeting of the JGA was held in 2013 and 7 excellent papers were presented on new molecular-targeted treatments for colorectal carcinomas and GI lymphoma. At the 10th annual meeting of the JGA, which was held in 2014, novel concepts of and therapeutic strategies for GI cancers, NET and GIST were discussed. In 2010, the WHO proposed a new classification system in which NET was classified into three categories - NET-G1, NET-G2 and NEC - dependent on proliferative activity, and the term 'carcinoid' was deleted. Regarding GIST, several management guidelines have already been published: by NCCN in 2004, by ESMO in 2005, and in Japan in 2006. The Japanese guidelines have recently been revised. In addition to the summaries of the annual meetings from 2012 to 2014, the major points of the recently revised Japanese guidelines for the diagnosis and management of GIST are described in this review.
Insights
This review summarizes advancements in diagnosing and treating gastrointestinal cancers, focusing on molecular-targeted therapies for gastrointestinal stromal tumors (GIST) and neuroendocrine tumors (NET). It highlights key findings from Japanese Gastroenterological Association meetings and revised GIST guidelines.
Area of Science:
- Gastroenterology
- Oncology
- Molecular Biology
Background:
- Japanese Gastroenterological Association (JGA) annual meetings consistently address gastrointestinal malignancy diagnostics and therapeutics.
- Recent focus includes molecular-targeted treatments for gastrointestinal stromal tumors (GIST), neuroendocrine tumors (NET), and GI cancers.
Purpose of the Study:
- To review progress in diagnostics and therapy for gastrointestinal cancers presented at JGA meetings (2012-2014).
- To summarize the recently revised Japanese guidelines for GIST diagnosis and management.
- To discuss novel concepts and therapeutic strategies for GI cancers, NET, and GIST.
Main Methods:
- Review of presentations from JGA annual scientific meetings (2012-2014).
- Analysis of the World Health Organization's 2010 classification of NET.
- Examination of published management guidelines for GIST (NCCN, ESMO, Japan) and the revised Japanese guidelines.
Main Results:
- JGA meetings showcased advancements in diagnostics and molecular-targeted therapies for GIST, colorectal carcinomas, and GI lymphoma.
- The WHO reclassified NET in 2010, removing the term 'carcinoid'.
- Revised Japanese guidelines for GIST diagnosis and management are available.
Conclusions:
- Continuous progress in molecular-targeted treatments is evident for various GI cancers.
- Updated guidelines are crucial for optimal management of GIST.
- The review provides insights into recent developments in gastroenterological oncology.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Tumor Immunotherapy
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

